Linda Powers

Linda Powers is the Chief Executive Officer at Northwest Biotherapeutics, a development stage biotechnology company specializing in immunotherapy products for treating cancer.

Northwest Biotherapeutics focuses on discovering, developing, and commercializing unique cancer vaccines known as immunotherapy products like DCVax(R). These vaccines are proven to be more effective, longer-lasting, easier to administer, cost-effective, and potentially applicable to a broader range of cancer patients compared to other active immune therapies.

The company boasts a deep product pipeline with multiple product lines and target cancers cleared for clinical trials by the FDA. Notably, Northwest Biotherapeutics stands out by conducting trials and manufacturing processes simultaneously in Europe and the US.

Clinical trials have shown that Northwest Biotherapeutics' cancer therapies can significantly extend time to recurrence and improve survival rates while maintaining a high quality of life with minimal side effects, distinguishing them from current treatment options.

With a strong focus on immunotherapy and cancer vaccine development, Linda Powers leads Northwest Biotherapeutics in its mission to revolutionize cancer treatment through innovative and impactful products.

As the CEO, Linda Powers drives the company's vision to enhance immune system responses to combat cancer effectively and improve patient outcomes with their advanced immunotherapy technologies.